|
|
|
|
|
by acqq
3907 days ago
|
|
Sounds really dangerous: https://wikileaks.org/tpp-ip3/pharmaceutical/Pharmaceutical%... "Marketing exclusivity for new forms and uses of old medicines could be considered a form of evergreening. Since marketing exclusivity applies regardless of the patent status of a drug, even off-patent medicines presented in the forms and uses described below would not have a generic competitor." |
|
My hope is that this particular issue will be bigger than they thought it would be due to the recent price issues around Daraprim (from $13.50 a pill to $750).